BDX - Becton, Dickinson and Company
| Previous Close | 235.24 |
| Open | 235.82 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 232.05 - 235.87 |
| 52 Week Range | 175.66 - 248.39 |
| Volume | 1,002,420 |
| Avg. Volume | 1,328,384 |
| Market Cap | 62.002B |
| Beta | 1.16 |
| PE Ratio (TTM) | 180.81 |
| EPS (TTM) | 1.29 |
| Earnings Date | May 3, 2018 |
| Forward Dividend & Yield | 3.00 (1.31%) |
| Ex-Dividend Date | 2018-03-08 |
| 1y Target Est | 252.06 |
Markit•3 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•4 days ago
BD Unveils Suite of Diagnostic Informatics and Automation Innovations
FRANKLIN LAKES, N.J., April 19, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today introduced several new informatics and automation solutions for clinical laboratories, which may play a critical role in the fight against infectious diseases and antimicrobial resistance. The new molecular, microbiology and software solutions will be showcased at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. The company announced the plan for the commercial availability of BD Synapsys™ microbiology informatics solution, which provides laboratories with secure connectivity across instruments and locations.
Markit•5 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
Markit•11 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BDX totaled $16.33 billion.
- Benzinga•12 days ago
Citi Projects 16% Upside For Becton Dickinson In Upgrade
Medical supplier Becton Dickinson and Co (NYSE: BDX ) is likely to outperform its own expectations, as well as the Street's, according to Citi. The Analyst Analyst Amit Hazan upgraded Becton Dickinson ...
- Market Realist•18 days ago
Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?
Should Investors Be Interested in Varian Medical Systems? Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution. Since the launch of this radiotherapy solution in 4Q16, the company has secured 57 orders, of which 19 were placed in 1Q18.
Markit•19 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BDX totaled $17.46 billion.
- PR Newswire•19 days ago
BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call
FRANKLIN LAKES, N.J. , April 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2018 earnings conference ...
- Market Realist•21 days ago
A Look at BDX’s Recent Launch and Its Applications
BDX's March 2018 Performance, Recommendations, and Updates
Market Realist•23 days agoBDX Divests Its Remaining Stake in Vyaire to Apax Partners
On March 19, 2018, Becton, Dickinson and Company (BDX) announced that it had entered into an agreement to divest its remaining stake in Vyaire Medical to Apax Partners for a cash payment of $435 million. Following the deal’s closure, Apax Partners will hold a 100% stake in Vyaire Medical. Vyaire Medical is a leading global respiratory care company.
Market Realist•23 days agoDiscussing BDX’s Recent Stock Price Performance
BDX's March 2018 Performance, Recommendations, and Updates
Market Realist•23 days agoAnalysts’ Recommendations on BD Stock in March 2018
BDX's March 2018 Performance, Recommendations, and UpdatesAnalysts’ latest recommendations
Market Realist•25 days agoBaxter International Created a New Reporting Structure for 2018
Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a range of one to six global businesses.
Market Realist•26 days agoBaxter International’s 2018 Revenues Expected to See Modest Rise
Who Is Watching Baxter International in March 2018? For fiscal 2017, Baxter International (BAX) reported revenues of ~$10.6 billion, which represents 4.0% YoY growth on a reported basis and a 5.0% rise on an operational basis. The company has projected its annual revenues for 2018 to be 6.0%–7.0% higher year-over-year (or YoY) on a reported basis.
Market Realist•26 days agoAnalysts’ March 2018 Ratings for Baxter International and Peers
Who Is Watching Baxter International in March 2018? Baxter International’s (BAX) top-line performance in 4Q17 was mainly driven by increased demand for the company’s Fluid Systems’ products. Baxter International also witnessed rising demand for its cytotoxic contract manufacturing services.
- Market Realist•26 days ago
A Look at Medtronic’s Technical Indicators
Medtronic Stock Hits 52-Week Low amid Trade War Fears
- Market Realist•26 days ago
Trade War Fears Triggered Medtronic’s Stock Decline on March 23
Medtronic Stock Hits 52-Week Low amid Trade War FearsMedtronic’s recent market performance
Markit•28 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
- PR Newswire•last month
BD Updates Instructions for Use for Certain BD Vacutainer® Blood Collection Tubes
FRANKLIN LAKES, N.J., March 22, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced it is updating the instructions for use of certain BD Vacutainer® tubes as part of its quality process to ensure that customers understand the appropriate uses of these products. Since BD became aware of the concerns about inaccurate lead test results from Magellan Diagnostics LeadCare® Testing Systems, the company has been cooperating fully with the U.S. Food and Drug Administration (FDA). BD launched an internal investigation and determined that Anodic Stripping Voltammetry (ASV) technology, which is used in Magellan LeadCare testing systems, is not compatible with thiuram, a material found in the rubber stoppers of the BD Vacutainer® EDTA Lavender, Pink and Tan top tubes and BD Vacutainer® Lithium Heparin Green top tubes.
- The Wall Street Journal•last month
[$$] Apax Buying Remaining Stake in Vyaire Medical for $435 Million
Apax Partners acquired a majority stake in Vyaire Medical, which previously was Becton Dickinson’s respiratory services business, in October 2016, with Becton Dickinson retaining a minority stake in the ...
- PR Newswire•last month
BD to Divest Remaining Investment in Vyaire Medical to Funds Managed by Apax Partners
FRANKLIN LAKES, N.J., March 19, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, announced today that it has signed a definitive agreement to divest its remaining, minority stake in Vyaire Medical to funds managed by Apax Partners. According to the terms of the agreement, BD will receive $435 million in cash for its remaining ownership of Vyaire Medical. BD intends to use the proceeds in line with its broader capital allocation strategy.
- Moody's•last month
Vyaire Medical, Inc -- Moody's assigns B3 CFR to Vyaire Medical; Outlook stable
Moody's Investors Service, ("Moody's") assigned a B3 Corporate Family Rating (CFR) and B3-PD Probability of Default Rating (PDR) to Vyaire Medical, Inc ("Vyaire"). Moody's also assigned ...
- Zacks•last month
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Markit•last monthSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
